Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Completed · Phase 3 · NCT04180488
Conditions: Chronic Spontaneous Urticaria
At a glance
- Research payments reported, 2025
- $30,125
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 397
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab SAR231893 (drug), Placebo (drug), non sedating H1-antihistamine (drug)
- Dates
- Started 2019-12-11; completion 2024-10-25
- Results posted
- Yes
Primary Objective: This study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders) Secondary Objectives: This study aimed to demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or hives, separately, at various timepoints This study aimed to demonstrate the efficacy of dupilumab on angioedema This study aimed to demonstrate the efficacy of dupilumab on urticaria control This study aimed to demonstrate improvement in health-related quality of life and overall disease status and sev…
From ClinicalTrials.gov, last updated 2025-08-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $30,125 in research payments for this study in 2025 (20 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hugh H. Windom, M.D. Allergy & Immunology · Sarasota, FL
- Brad H. Goodman, M. D. Allergy & Immunology · Savannah, GA
- Lee S. Clore JR., M.D. Allergy & Immunology · Owensboro, KY
- Michael J. Palumbo, M.D. Allergy & Immunology · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hugh Windom, MD, PA Sarasota Clinical $8,696
- $7,750
- Aeroallergy Research Laboratories of Savannah Inc $4,700
- Allergy and Clinical Immunology Associates, PC $4,538
- Allergy and Asthma Specialists, Psc $4,441
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.